Abstract 327P
Background
SARS-CoV-2 is a novel coronavirus of zoonotic origin that emerged in China and now is spreading worldwide. 71 838 cases have been registered in Kazakhstan. At the moment, 3 585 of which died. The risk of coronavirus infection in oncohematological patients is much higher, due to a reduced immune status and immunosuppressive therapy, which they receive, as well as comorbidity in majority of patients.
Methods
We included all consecutive adult patients with oncohematologic diseases admitted to KazIOR, the Hematology Department, with laboratory-confirmed COVID-19 infection between June 15 and July 15, 2020. A confirmed case of COVID-19 was defined by a positive result on a real-time RT-PCR assay and radiological evidence of pneumonia CT-scan.
Results
The median patient age was 49 (range, 18–81) years, 64% were male. The median duration of symptoms before the COVID-19 PCR assay was was 4 (range, 0–22) days. Multiple myeloma (MM) was eleven patients, Acute Lymphoblastic leukemia (ALL)-three patients, Non-Hodgkin lymphoma (NHL)-three patients, Hodgkin Lymphoma (HL)-five patients, Chronic Lymphocytic leukemia (CLL)-two patients. 16 from 25 patients (64%) received chemotherapy at the time of COVID-19 diagnosis, which was registered during the treatment or after that. 13 patients had clinical symptoms, such as fever (n = 56%), cough (n = 25.8%), and shortness of breath (n = 48%), twelve patients were asymptomatic. CT scan of the chest was performed in 14 patients and bilateral ground glass opacities were evident in all cases. Five patients died, among them three patients died from the acute respiratory distress syndrome (ARDS), two patients with ALL had a progression of the process during chemotherapy, which was aggravated by the ARDS syndrome and acute renal failure.
Conclusions
Despite positive COVID-19 status patients with oncohematologic diseases require urgent specific treatment. The virus SARS-CoV-2 worsens the condition of comorbid patients, the response to treatment, increases the possible emergence of resistant and refractory patients, due to the lengthening of the inter-course periods. Risk factors as older age, and comorbidities such as diabetes, hypertension, or cardiac disease can aggravate patient condition which were confirmed by scientific research data.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
275P - Weekly paclitaxel, carboplatin and cetuximab (PCC) combination followed by nivolumab in platinum-sensitive recurrent and /or metastatic squamous cell carcinoma of head and neck: A double institution retrospective analysis from India
Presenter: Vivek Agarwala
Session: e-Poster Display Session
276P - Sarcopenia to predict overall survival in head and neck cancer patients receiving chemotherapy: A systematic review and meta-analysis
Presenter: Felix Kwenandar
Session: e-Poster Display Session
277P - Tegafur/uracil, platinum and cetuximab (UPEx) as first line treatment in frail patients with recurrent or metastatic head and neck squamous cell carcinoma
Presenter: Meng-che Hsieh
Session: e-Poster Display Session
278P - Serial assessment of parotid volume changes during radical chemoradiation of locally advanced head and neck cancer: Its implications in practice of adaptive radiotherapy
Presenter: Aathira T S
Session: e-Poster Display Session
279P - Clinico pathological characteristics and survival outcome in oral cavity cancer with masticator space involvement (T4b): A retrospective single institutional experience
Presenter: Abdulla Kunnummal Palathinkara
Session: e-Poster Display Session
280P - Safety and efficacy of concurrent chemoradiotherapy for head and neck cancers in younger versus older patients: Post hoc analysis of a randomized control trial
Presenter: Vanita Noronha
Session: e-Poster Display Session
281P - Prevalence of premalignant lesions and oral cancer among tobacco-using tea plantation workers of Nilgiri Hills, Tamilnadu, India
Presenter: Delfin Lovelina Francis
Session: e-Poster Display Session
282P - Filipino head and neck cancer patients and their quality of life
Presenter: Frederic Ivan Ting
Session: e-Poster Display Session
283P - Descriptive epidemiology of head and neck cancer in Niger: First results from the National Cancer Registry
Presenter: Salamatou Mamoudou Garba
Session: e-Poster Display Session
284P - Outcomes of metronomic adjuvant chemotherapy with tegafur-uracil in locally advanced head and neck squamous cell carcinoma
Presenter: Tsung-jang Yeh
Session: e-Poster Display Session